Robust antigen-specific CD8 T cell tolerance to a model prostate cancer neoantigen

References

• Siegel RL, Miller KD, Jemal a. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–9. doi:10.3322/caac.21590.
   PubMed Web of Science ®Google Scholar
• Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010;10:580–593. doi:10.1038/nri2817.
   PubMed Web of Science ®Google Scholar
• Mao W, Drake CG. Immunotherapy for Prostate Cancer: An Evolving Landscape. In: Laurence Zitvogel & Guido Kroemer, editors. Oncoimmunology: a practical guide for cancer immunotherapy. Berlin, Heidelberg: Springer; 2018. p. 593–606.
   Google Scholar
• Cordes LM, Gulley JL, Madan RA. Perspectives on the clinical development of immunotherapy in prostate cancer. Asian J Androl. 2018;20:253–259. doi:10.4103/aja.aja_9_18.
   PubMed Web of Science ®Google Scholar
• Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJM, Krainer M, Houede N, Santos R, Mahammedi H, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:700–712. doi:10.1016/S1470-2045(14)70189-5.
   PubMed Web of Science ®Google Scholar
• Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, Humanski P, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35:40–47. doi:10.1200/JCO.2016.69.1584.
   PubMed Web of Science ®Google Scholar
• Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, et al. Results of PROSPECT: a randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer. J Clin Oncol. 2018;36:5006. doi:10.1200/JCO.2018.36.15_suppl.5006.
   Google Scholar
• Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H, Niknafs N, White JR, Silberstein JL, Sullivan R, et al. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget. 2018;9:28561–28571. doi:10.18632/oncotarget.25564.
   PubMedGoogle Scholar
• Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, Vaishampayan U, Berger R, Sezer A, Alanko T, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38:395–405. doi:10.1200/JCO.19.01638.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–422. doi:10.1056/NEJMoa1001294.
   PubMed Web of Science ®Google Scholar
• Morgan DJ, Kreuwel HT, Sherman LA. Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. J Immunol. 1999;163:723–727.
   PubMed Web of Science ®Google Scholar
• Drake CG, Doody ADH, Mihalyo MA, Huang C-T, Kelleher E, Ravi S, Hipkiss EL, Flies DB, Kennedy EP, Long M, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell. 2005;7:239–249. doi:10.1016/j.ccr.2005.01.027.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–998. doi:10.1038/ni1102-991.
   PubMed Web of Science ®Google Scholar
• Emens LA. Cancer vaccines: on the threshold of success. Expert Opin Emerg Drugs. 2008;13:295–308. doi:10.1517/14728214.13.2.295.
   PubMed Web of Science ®Google Scholar
• Jackson SR, Yuan J, Teague RM. Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy. 2014;6:833–852. doi:10.2217/imt.14.51.
   PubMed Web of Science ®Google Scholar
• Bruno TC, Rothwell C, Grosso JF, Getnet D, Yen HR, Durham NM, Netto G, Pardoll DM, Drake CG. Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model. Prostate. 2012;72:514–522. doi:10.1002/pros.21453.
   PubMed Web of Science ®Google Scholar
• Lees JR, Charbonneau B, Swanson AK, Jensen R, Zhang J, Matusik R, Ratliff TL. Deletion is neither sufficient nor necessary for the induction of peripheral tolerance in mature CD8+ T cells. Immunology. 2006;117:248–261. doi:10.1111/j.1365-2567.2005.02293.x.
   PubMed Web of Science ®Google Scholar
• Bai A, Higham E, Eisen HN, Wittrup KD, Chen J. Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc Natl Acad Sci USA. 2008;105:13003–13008. doi:10.1073/pnas.0805599105.
   PubMed Web of Science ®Google Scholar
• Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, MalyguineA, Alvord WG, Greenberg NM, Hurwitz AA. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res. 2009;69:6256–6264. doi:10.1158/0008-5472.CAN-08-4516.
   PubMed Web of Science ®Google Scholar
• Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI, Muller WJ, Dixon KH, Jaffee EM. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 2000;60:3569–3576.
   PubMed Web of Science ®Google Scholar
• Sunay MM, Foote JB, Leatherman JM, Edwards JP, Armstrong TD, Nirschl CJ, Hicks J, Emens LA. Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. Int Immunopharmacol. 2017;46:112–123. doi:10.1016/j.intimp.2017.02.028.
   PubMed Web of Science ®Google Scholar
• Black CM, Armstrong TD, Jaffee EM. Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice. Cancer Immunol Res. 2014;2:307–319. doi:10.1158/2326-6066.CIR-13-0145.
   PubMed Web of Science ®Google Scholar
• Watson PA, Ellwood-Yen K, King JC, Wongvipat J, LeBeau MM, Sawyers CL. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res. 2005;65:11565–11571. doi:10.1158/0008-5472.CAN-05-3441.
   PubMed Web of Science ®Google Scholar
• Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, Sawyers CL. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell. 2003;4:223–238. doi:10.1016/s1535-6108(03)00197-1.
   PubMed Web of Science ®Google Scholar
• Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and Prostate Cancer. Genes Cancer. 2010;1:617–628. doi:10.1177/1947601910379132.
   PubMedGoogle Scholar
• Ercolini AM, Machiels JPH, Chen YC, Slansky JE, Giedlen M, Reilly RT, Jaffee EM. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol. 2003;170:4273–4280. doi:10.4049/jimmunol.170.8.4273.
   PubMed Web of Science ®Google Scholar
• Sakamoto C, Kohara H, Inoue H, Narusawa M, Ogawa Y, Hirose-Yotsuya L, Miyamoto S, Matsumura Y, Yamada K, Takahashi A, et al. Therapeutic vaccination based on side population cells transduced by the granulocyte-macrophage colony-stimulating factor gene elicits potent antitumor immunity. Cancer Gene Ther. 2017;24:165–174. doi:10.1038/cgt.2016.80.
   PubMed Web of Science ®Google Scholar
• Dranoff G, Jaffee E, LazenbyA, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539–3543. doi:10.1073/pnas.90.8.3539.
   PubMed Web of Science ®Google Scholar
• Arlen PM, Mohebtash M, Madan RA, Gulley JL. Promising novel immunotherapies and combinations for prostate cancer. Future Oncol. 2009;5:187–196. doi:10.2217/14796694.5.2.187.
   PubMed Web of Science ®Google Scholar
• Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014;11:509–524. doi:10.1038/nrclinonc.2014.111.
   PubMed Web of Science ®Google Scholar
• Martins KA, Bavari S, Salazar AM. Vaccine adjuvant uses of poly-IC and derivatives. Expert Rev Vaccines. 2015;14:447–459. doi:10.1586/14760584.2015.966085.
   PubMed Web of Science ®Google Scholar
• Garzon-Muvdi T, Theodros D, Luksik AS, Maxwell R, Kim E, Jackson CM, Belcaid Z, Ganguly S, Tyler B, Brem H, et al. Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma. Oncotarget. 2018;9:20681–20697. doi:10.18632/oncotarget.25061.
   PubMedGoogle Scholar
• Shen YC, Ghasemzadeh A, Kochel CM, Nirschl TR, Francica BJ, Lopez-Bujanda ZA, Carrera Haro MA, Tam A, Anders RA, Selby MJ, et al. Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model. Prostate Cancer Prostatic Dis. 2018;21:113–125. doi:10.1038/s41391-017-0013-x.
   PubMed Web of Science ®Google Scholar
• Lopez-Bujanda ZA, Haffner MC, Chaimowitz MG, Chowdhury N, Venturini NJ, Obradovic A, Hansen CS, Jacków J, Sfanos KS, Bieberich CJ, et al. Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression. bioRxiv. 2019;651083. doi:10.1101/651083.
   Google Scholar
• Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA. 1995;92:3439–3443. doi:10.1073/pnas.92.8.3439.
   PubMed Web of Science ®Google Scholar
• Obradovic AZ, Dallos MC, Zahurak ML, Partin AW, Schaeffer EM, Ross AE, Allaf ME, Nirschl TR, Liu D, Chapman CG, et al. T-cell infiltration and adaptive treg resistance in response to androgen deprivation with or without vaccination in localized prostate cancer. Clin Cancer Res. 2020;26:3182–3192. doi:10.1158/1078-0432.CCR-19-3372.
   PubMed Web of Science ®Google Scholar
• Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, Kaplan RN, Mackall CL. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med. 2014;6:237ra267. doi:10.1126/scitranslmed.3007974.
   Web of Science ®Google Scholar
• Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 2000;60:2444–2448.
   PubMed Web of Science ®Google Scholar
• Jayaprakash P, Ai M, Liu a, Budhani P, Bartkowiak T, Sheng J, Ager C, Nicholas C, Jaiswal AR, Sun Y, et al. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. J Clin Invest. 2018;128:5137–5149. doi:10.1172/JCI96268.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Guo C, Gurel B, De Marzo AM, Sfanos KS, Mani RS, Gil J, Drake CG, Alimonti A. Prostate carcinogenesis: inflammatory storms. Nat Rev Cancer. 2020;20:455–469. doi:10.1038/s41568-020-0267-9.
   PubMed Web of Science ®Google Scholar
• Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate. 2002;52:20–33. doi:10.1002/pros.10091.
   PubMed Web of Science ®Google Scholar
• Weiss VL, Lee TH, Song H, Kouo TS, Black CM, Sgouros G, Jaffee EM, Armstrong TD. Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. PLoS One. 2012;7:e31962. doi:10.1371/journal.pone.0031962.
   PubMed Web of Science ®Google Scholar
• Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell. 1986;45:649–657. doi:10.1016/0092-8674(86)90779-8.
   PubMed Web of Science ®Google Scholar